The venture capital funding volume raised by European life sciences companies from U.S. investors has experienced an extraordinary growth so far. As of end of August 2021, the gross volume amounts to EUR 3.1bn, which has already exceeded the volume of the whole year 2020 by 24% (EUR 2.5bn).
However, the number of deals with U.S. participation only amounts to 134 in 2021 so far which is still below the total number of 2020 (157 deals).
It is notable that the number of larger deals with U.S. participation has significantly increased within the last years. The number of deals with a volume > EUR 30m amounted to 21 in 2018 and 22 in 2019. In 2020, it increased to 38. As of end of August 2021, there have already been 53 fundraisings in this range, confirming the trend towards larger financing rounds in the life sciences sector.
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: